In order to investigate the clinical efficacy of DMAb in combination with anti-PD1 immunotherapy, we retrospectively included 119 patients with NSCLC-BoM who were treated at FUSCC between March 2018 and June 2023 (Clinical cohort 3 at FUSCC, total n=119). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.